Quotes for Arcede Pharma AB
Right Now
- +/-
- %
- Latest
- High
- Low
- Volume
- Turnover ()
- Time (Latest trade)
Board
CEO
- Erik Magnusson (tf)
Chairperson of the Board
- Ingemar Kihlström
Board
- Åsa Kornfeld
- Johanna Asklin
- Laurent Pacheco
Arcede Pharma is a pharmaceutical company. The company conducts research and development in the field of chronic obstructive pulmonary disease, also abbreviated as COPD, and severe asthma. The company's product portfolio includes medicines intended for the treatment and relief of the above ailments. The largest activity is found within the Nordic market. The company was created via a spin-off of Respiratorius in 2022 and today has its headquarters in Lund.
News agencies
- Finwire: Arcede Pharmas styrelse föreslås till omval
- Finwire: Arcede Pharma får data från studie med RCD405 publicerad i vetenskaplig tidskrift
- Finwire: Arcede Pharma rapporterar som planerat ingen omsättning
- Finwire: Arcede Pharma tillförs 4,6 miljoner kronor från utnyttjande av teckningsoptioner
- Finwire: Arcede Pharmas finanschef Erik Magnusson utsedd till tillförordnad vd
Largest Owners
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Christer Fåhraeus | 13,66 | 13,66 | 2024-03-26 |
| Avanza Pension | 7,79 | 7,79 | 2024-03-26 |
| Ben Hayes | 4,13 | 4,13 | 2024-03-26 |
| Tord Holmberg | 3,64 | 3,64 | 2024-03-26 |
| Hans Harvig | 2,47 | 2,47 | 2024-03-26 |
| Christian Lentz | 2,13 | 2,13 | 2024-03-26 |
| Hans Jönsson | 1,78 | 1,78 | 2024-03-26 |
| Christian Müller | 1,77 | 1,77 | 2024-03-26 |
| Hans Mandahl | 1,48 | 1,48 | 2024-03-26 |
| Konsult I Beddingestrand AB | 1,25 | 1,25 | 2024-03-26 |
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.
Insider trading
Key Numbers
*Compiled data from Millistream
Upcoming reports
-
2024-05-16 Årsstämma 2023
-
2024-05-16 Delårsrapport 2024-Q1
-
2024-08-28 Delårsrapport 2024-Q2
-
2024-11-25 Delårsrapport 2024-Q3